Real-World Diagnostic and Therapeutic Insights in Transthyretin Cardiac Amyloidosis: Experience from the Black Sea Region of Türkiye
Open Access
- 2 January 2026
- journal article
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (6) , 351-354
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Impact of Tafamidis on survival in elderly patients: Insights from the Healthcare European Amyloidosis RegistryInternational Journal of Cardiology, 2025
- Race, Genetics, and Social Determinants of Health in Transthyretin Cardiac Amyloidosis: A Literature Review and Call to ActionCurrent Cardiology Reports, 2025
- Is transthyretin amyloid cardiomyopathy heading towards losing its rare disease classification?Expert Review of Cardiovascular Therapy, 2025
- Association Between Triglyceride-Glucose Index and Prognosis of Patients with Hypertrophic Cardiomyopathy and Heart Failure with Preserved Ejection FractionThe Anatolian Journal of Cardiology, 2025
- Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi studyFrontiers in Cardiovascular Medicine, 2024
- Transthyretin amyloidosis cardiomyopathy in Greece: Clinical insights from the National Referral CenterHellenic Journal of Cardiology, 2023
- Assessment of clinical characteristics of cardiac amyloidosis as a potential underlying etiology in patients diagnosed with heart failure with preserved ejection fractionPolish Heart Journal, 2022
- Early Experience of Tafamidis Treatment in Japanese Patients With Wild-Type Transthyretin Cardiac Amyloidosis From the Kochi Amyloidosis CohortCirculation Journal, 2022
- The Impact of Patients With Cardiac Amyloidosis in HFpEF TrialsJACC: Heart Failure, 2021
- Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine, 2018